Clinical Efficacy, Antibiotic Resistance Genes, Virulence Factors and Outcome of Hospital-Acquired Pneumonia Induced by Klebsiella pneumoniae Carbapenemase 2-Producing with Tigecycline Treatment in the ICU

PURPOSE: Tigecycline is an agent for carbapenemase-producing Klebsiella pneumonia (KPC-KP), given its penetration into lung tissues. Our study focused on the molecular and clinical efficacy of tigecycline for hospital-acquired pneumonia (HAP) in the ICU. PATIENTS AND METHODS: A retrospective cohort...

Descripción completa

Detalles Bibliográficos
Autores principales: Bai, Xiang-Rong, Cao, Jing-Rong, Wang, Zhi-Zhou, Li, Wen-Chao, Chen, Dian-Dian, Lou, Ran, Qu, Xin, Yan, Su-Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9509680/
https://www.ncbi.nlm.nih.gov/pubmed/36168639
http://dx.doi.org/10.2147/IDR.S381280

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9509680/
https://www.ncbi.nlm.nih.gov/pubmed/36168639
http://dx.doi.org/10.2147/IDR.S381280

Ejemplares similares